EUCTR2005-000557-30-IT进行中（未招募）不适用
A phase II, open-label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab Omnitarg , a recombinant humanized antibody against HER2, in combination with carboplatin-based standard chemotherapy versus carboplatin-based standard chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 148
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute-on-chronic liver failure) who experience accumulation of fluid in the abdominal cavity (called ascites) as well as intellectual, behavioral decay and physical decayCTIS2024-513706-56-00Versantis AG97
进行中（未招募）
1 期
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute-on-chronic liver failure) who experience accumulation of fluid in the abdominal cavity (called ascites) as well as intellectual, behavioral decay and physical decay.Acute-on-chronic liver failure (ACLF) is characterized by hepatic andextrahepatic organ dysfunction and/or failure and highly activatedsystemic inflammation. It leads to an accumulation of different metabolites, interalias ammonia, which cannot be metabolized.Hyperammonemia leads to Hepatic Encephalopathy (HE). ACLF is amajor cause of death in cirrhosis, with an approximately 50% mortality rate. The selected patient population is ACLF grade 1 and 2 patients with ascites.MedDRA version: 24.0Level: PTClassification code 10077305Term: Acute on chronic liver failureSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-002617-33-DEVersantis AG60
进行中（未招募）
1 期
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute-on-chronic liver failure) who experience accumulation of fluid in the abdominal cavity (called ascites) as well as intellectual, behavioral decay and physical decay.EUCTR2021-002617-33-ESVersantis AG70
进行中（未招募）
1 期
A clinical study to evaluate a new medicinal product VS-01 in patients withan acute episode on top of a chronic liver disease (called acute-on-chronicliver failure) who experience accumulation of fluid in the abdominal cavity(called ascites) as well as intellectual, behavioral decay and physicaldecay.Acute-on-chronic liver failure (ACLF) is characterized by hepatic and extrahepatic organ dysfunction and/or failure and highly activated systemic inflammation. It leads to an accumulation of different metabolites, interalias ammonia, which cannot be metabolized. Hyperammonemia leads to Hepatic Encephalopathy (HE). ACLF is a major cause of death in cirrhosis, with an approximately 50% mortality rate. The selected patient population is ACLF grade 1 and 2 patients with ascites.MedDRA version: 24.0Level: PTClassification code 10077305Term: Acute on chronic liver failureSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-002617-33-FRVersantis AG60
进行中（未招募）
1 期
A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute-on-chronic liver failure) who experience accumulation of fluid in the abdominal cavity (called ascites) as well as intellectual, behavioral decay and physical decay.EUCTR2021-002617-33-BEVersantis AG60